• Je něco špatně v tomto záznamu ?

Crystal structures of the complex of a kallikrein inhibitor from Bauhinia bauhinioides with trypsin and modeling of kallikrein complexes

M. Li, J. Srp, A. Gustchina, Z. Dauter, M. Mares, A. Wlodawer,

. 2019 ; 75 (Pt 1) : 56-69. [pub] 20190107

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19027908

Grantová podpora
HHSN261200800001E National Cancer Institute
Intramural funds National Cancer Institute
CZ.02.1.01/0.0/0.0/16_019/0000729 European Regional Development Fund, ChemBioDrug
RVO 61388963 Ústav Organické Chemie a Biochemie, Akademie Věd České Republiky

Structures of a recombinant Kunitz-type serine protease inhibitor from Bauhinia bauhinioides (BbKI) complexed with bovine trypsin were determined in two crystal forms. The crystal structure with the L55R mutant of BbKI was determined in space group P64 at 1.94 Å resolution and that with native BbKI in the monoclinic space group P21 at 3.95 Å resolution. The asymmetric unit of the latter crystals contained 44 independent complexes, thus representing one of the largest numbers of independent objects deposited in the Protein Data Bank. Additionally, the structure of the complex with native BbKI was determined at 2.0 Å resolution from P64 crystals isomorphous to those of the mutant. Since BbKI has previously been found to be a potent inhibitor of the trypsin-like plasma kallikrein, it was also tested against several tissue kallikreins. It was found that BbKI is a potent inhibitor of human tissue kallikrein 4 (KLK4) and the chymotrypsin-like human tissue kallikrein 7 (KLK7). Structures of BbKI complexed with the catalytic domain of human plasma kallikrein were modeled, as well as those with KLK4 and KLK7, and the structures were analyzed in order to identify the interactions that are responsible for inhibitory potency.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19027908
003      
CZ-PrNML
005      
20190816093011.0
007      
ta
008      
190813s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1107/S2059798318016492 $2 doi
035    __
$a (PubMed)30644845
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Li, Mi $u Macromolecular Crystallography Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
245    10
$a Crystal structures of the complex of a kallikrein inhibitor from Bauhinia bauhinioides with trypsin and modeling of kallikrein complexes / $c M. Li, J. Srp, A. Gustchina, Z. Dauter, M. Mares, A. Wlodawer,
520    9_
$a Structures of a recombinant Kunitz-type serine protease inhibitor from Bauhinia bauhinioides (BbKI) complexed with bovine trypsin were determined in two crystal forms. The crystal structure with the L55R mutant of BbKI was determined in space group P64 at 1.94 Å resolution and that with native BbKI in the monoclinic space group P21 at 3.95 Å resolution. The asymmetric unit of the latter crystals contained 44 independent complexes, thus representing one of the largest numbers of independent objects deposited in the Protein Data Bank. Additionally, the structure of the complex with native BbKI was determined at 2.0 Å resolution from P64 crystals isomorphous to those of the mutant. Since BbKI has previously been found to be a potent inhibitor of the trypsin-like plasma kallikrein, it was also tested against several tissue kallikreins. It was found that BbKI is a potent inhibitor of human tissue kallikrein 4 (KLK4) and the chymotrypsin-like human tissue kallikrein 7 (KLK7). Structures of BbKI complexed with the catalytic domain of human plasma kallikrein were modeled, as well as those with KLK4 and KLK7, and the structures were analyzed in order to identify the interactions that are responsible for inhibitory potency.
650    _2
$a zvířata $7 D000818
650    _2
$a Bauhinia $x chemie $7 D036481
650    _2
$a skot $7 D002417
650    _2
$a krystalografie rentgenová $7 D018360
650    _2
$a lidé $7 D006801
650    _2
$a kalikreiny $x antagonisté a inhibitory $x chemie $7 D007610
650    _2
$a molekulární modely $7 D008958
650    _2
$a rostlinné proteiny $x chemie $7 D010940
650    _2
$a trypsin $x chemie $7 D014357
655    _2
$a časopisecké články $7 D016428
700    1_
$a Srp, Jaroslav $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, 166 10 Prague, Czech Republic.
700    1_
$a Gustchina, Alla $u Macromolecular Crystallography Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
700    1_
$a Dauter, Zbigniew $u Synchrotron Radiation Research Section, Macromolecular Crystallography Laboratory, NCI, Argonne National Laboratory, Argonne, IL 60439, USA.
700    1_
$a Mares, Michael $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, 166 10 Prague, Czech Republic.
700    1_
$a Wlodawer, Alexander $u Macromolecular Crystallography Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
773    0_
$w MED00195158 $t Acta crystallographica. Section D, Structural biology $x 2059-7983 $g Roč. 75, č. Pt 1 (2019), s. 56-69
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30644845 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190816093240 $b ABA008
999    __
$a ok $b bmc $g 1433057 $s 1066368
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 75 $c Pt 1 $d 56-69 $e 20190107 $i 2059-7983 $m Acta crystallographica. Section D, Structural biology $n Acta Crystallogr D Struct Biol $x MED00195158
GRA    __
$a HHSN261200800001E $p National Cancer Institute
GRA    __
$a Intramural funds $p National Cancer Institute
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000729 $p European Regional Development Fund, ChemBioDrug
GRA    __
$a RVO 61388963 $p Ústav Organické Chemie a Biochemie, Akademie Věd České Republiky
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...